Cargando…
Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo
The anticancer activity of Curaxin CBL0137, a DNA-binding small molecule with chromatin remodulating effect, has been demonstrated in different cancers. Herein, a comparative evaluation of CBL0137 activity was performed in respect to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL),...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856019/ https://www.ncbi.nlm.nih.gov/pubmed/36672738 http://dx.doi.org/10.3390/biomedicines11010230 |
_version_ | 1784873518457946112 |
---|---|
author | Fetisov, Timur I. Borunova, Anna A. Antipova, Alina S. Antoshina, Elena E. Trukhanova, Lubov S. Gorkova, Tatyana G. Zuevskaya, Svetlana N. Maslov, Alexei Gurova, Katerina Gudkov, Andrei Lesovaya, Ekaterina A. Belitsky, Gennady A. Yakubovskaya, Marianna G. Kirsanov, Kirill I. |
author_facet | Fetisov, Timur I. Borunova, Anna A. Antipova, Alina S. Antoshina, Elena E. Trukhanova, Lubov S. Gorkova, Tatyana G. Zuevskaya, Svetlana N. Maslov, Alexei Gurova, Katerina Gudkov, Andrei Lesovaya, Ekaterina A. Belitsky, Gennady A. Yakubovskaya, Marianna G. Kirsanov, Kirill I. |
author_sort | Fetisov, Timur I. |
collection | PubMed |
description | The anticancer activity of Curaxin CBL0137, a DNA-binding small molecule with chromatin remodulating effect, has been demonstrated in different cancers. Herein, a comparative evaluation of CBL0137 activity was performed in respect to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia and multiple myeloma (MM) cultured in vitro. MTT assay showed AML and MM higher sensitivity to CBL0137’s cytostatic effect comparatively to other hematological malignancy cells. Flow cytometry cell cycle analysis revealed an increase in subG1 and G2/M populations after CBL0137 cell treatment, but the prevalent type of arrest varied. Apoptosis activation by CBL0137 measured by Annexin-V/PI dual staining was more active in AML and MM cells. RT2 PCR array showed that changes caused by CBL0137 in signaling pathways involved in cancer pathogenesis were more intensive in AML and MM cells. On the murine model of AML WEHI-3, CBL0137 showed significant anticancer effects in vivo, which were evaluated by corresponding changes in spleen and liver. Thus, more pronounced anticancer effects of CBL0137 in vitro were observed in respect to AML and MM. Experiments in vivo also indicated the perspective of CBL0137 use for AML treatment. This in accordance with the frontline treatment approach in AML using epigenetic drugs. |
format | Online Article Text |
id | pubmed-9856019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98560192023-01-21 Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo Fetisov, Timur I. Borunova, Anna A. Antipova, Alina S. Antoshina, Elena E. Trukhanova, Lubov S. Gorkova, Tatyana G. Zuevskaya, Svetlana N. Maslov, Alexei Gurova, Katerina Gudkov, Andrei Lesovaya, Ekaterina A. Belitsky, Gennady A. Yakubovskaya, Marianna G. Kirsanov, Kirill I. Biomedicines Article The anticancer activity of Curaxin CBL0137, a DNA-binding small molecule with chromatin remodulating effect, has been demonstrated in different cancers. Herein, a comparative evaluation of CBL0137 activity was performed in respect to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia and multiple myeloma (MM) cultured in vitro. MTT assay showed AML and MM higher sensitivity to CBL0137’s cytostatic effect comparatively to other hematological malignancy cells. Flow cytometry cell cycle analysis revealed an increase in subG1 and G2/M populations after CBL0137 cell treatment, but the prevalent type of arrest varied. Apoptosis activation by CBL0137 measured by Annexin-V/PI dual staining was more active in AML and MM cells. RT2 PCR array showed that changes caused by CBL0137 in signaling pathways involved in cancer pathogenesis were more intensive in AML and MM cells. On the murine model of AML WEHI-3, CBL0137 showed significant anticancer effects in vivo, which were evaluated by corresponding changes in spleen and liver. Thus, more pronounced anticancer effects of CBL0137 in vitro were observed in respect to AML and MM. Experiments in vivo also indicated the perspective of CBL0137 use for AML treatment. This in accordance with the frontline treatment approach in AML using epigenetic drugs. MDPI 2023-01-16 /pmc/articles/PMC9856019/ /pubmed/36672738 http://dx.doi.org/10.3390/biomedicines11010230 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fetisov, Timur I. Borunova, Anna A. Antipova, Alina S. Antoshina, Elena E. Trukhanova, Lubov S. Gorkova, Tatyana G. Zuevskaya, Svetlana N. Maslov, Alexei Gurova, Katerina Gudkov, Andrei Lesovaya, Ekaterina A. Belitsky, Gennady A. Yakubovskaya, Marianna G. Kirsanov, Kirill I. Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo |
title | Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo |
title_full | Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo |
title_fullStr | Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo |
title_full_unstemmed | Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo |
title_short | Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo |
title_sort | targeting features of curaxin cbl0137 on hematological malignancies in vitro and in vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856019/ https://www.ncbi.nlm.nih.gov/pubmed/36672738 http://dx.doi.org/10.3390/biomedicines11010230 |
work_keys_str_mv | AT fetisovtimuri targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT borunovaannaa targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT antipovaalinas targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT antoshinaelenae targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT trukhanovalubovs targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT gorkovatatyanag targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT zuevskayasvetlanan targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT maslovalexei targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT gurovakaterina targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT gudkovandrei targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT lesovayaekaterinaa targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT belitskygennadya targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT yakubovskayamariannag targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo AT kirsanovkirilli targetingfeaturesofcuraxincbl0137onhematologicalmalignanciesinvitroandinvivo |